Summarize the challenges associated with treating schizophrenia with D2-blocking antipsychotics Assess the MOAs of selective muscarinic receptor activators for schizophrenia Evaluate the latest clinical data associated with the safety, tolerability, and efficacy of selective muscarinic receptor activators for schizophrenia
- Provider:HMP Education
- Activity Link: https://www.hmpeducation.com/program/24-elevate-101-3
- Start Date: 2024-06-28 05:00:00
- End Date: 2024-06-28 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours
Psychology: 1.0 hours
Social Work: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: Source: Cerevel Therapeutics - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest